Agrow is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. Please do not redistribute without permission.

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MBI gains licence to endophyte for drought tolerance

The US biopesticide company, Marrone Bio Innovations (MBI - Davis, California), has gained an exclusive licence to various uses of an unnamed plant endophyte from Brookhaven Science Associates, which manages the US Department of Energy's Brookhaven National Laboratory (Upton, New York). The deal grants MBI exclusive commercial development and marketing rights to horticultural uses of the endophyte in the US, Canada, Mexico, New Zealand, Australia and member states of the European Patent Organisation. The licensed properties are directed at promoting increased yield and providing drought tolerance. MBI is developing several products aimed at promoting growth through reduced water loss. They are expected to be the first of their kind on the market. Earlier this year, MBI gained a licence from the Japanese Kao Corporation for an active ingredient aimed at boosting yields through stress resistance (Agrow No 682, p 2).

Advertisement

Topics

What to read next

Advertisement
UsernamePublicRestriction

Register

AG001905

Ask The Analyst

Please fill in the form below to send over your enquiry or check the Ask The Analyst Page to find out more about the service

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel